- Joined
- 8 June 2008
- Posts
- 13,313
- Reactions
- 19,685
Was supposed to be blacklisted for me since late last year. none of my systems sneaked it in.did check..
That company has already burnt enough of my money.?
Was supposed to be blacklisted for me since late last year. none of my systems sneaked it in.did check..Looks like a few companies going into financial trouble !
This one which could be considered big based on Market Cap and recently another spec OLI which is suspended having run out of money
In the process we get sliced up being the shareholders
I did buy a few back in early February at $2.69. Liked the fact the back pain therapy worked.@Knobby22 hope you did not give in and bought back in.one of your pet stock but i believe we can agree : great idea.concept but not a great company
Bought back in at 2.25........ Still think its worth keeping an eye on but its a biotech so you have to be nimble.
......
But you will suffer less when it will fall 30% in a day or 2 ,afer some bad news or the next SPP...Mesoblast has entered into a license and collaboration agreement with Novartis for the development, manufacture, and commercialization of remestemcel-L, with an initial focus on the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19. The agreement remains subject to certain closing conditions, including time to analyze the results from this COVID-19 ARDS trial
Enough to have a punt in the tipping comp.
Have an unfulfilled buy order at 1.865.
I expect it to remain unfulfilled and make me suffer as it climbs back of the canvas.
Mesoblast has entered into a license and collaboration agreement with Novartis for the development, manufacture, and commercialization of remestemcel-L, with an initial focus on the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19. The agreement remains subject to certain closing conditions, including time to analyze the results from this COVID-19 ARDS trial
Enough to have a punt in the tipping comp.
Have an unfulfilled buy order at 1.865.
I expect it to remain unfulfilled and make me suffer as it climbs back of the canvas.
While I agree with most of this I am having a speccy in the Tipping thread.Re: MSB - Mesoblast
MSB has no income and is really a high priced biotech spekkie and I treat it as such. The trick will be to be in it for the longer term at the right time when the products are confirmed as ready to be commercialised.
Cheers
Country Lad
Ha ha, that quote was 8 years ago @UMike and they now has a whole $7.4 mil income. Unfortunately this needs to be taken in the context of the $100 mil loss, so the quote is probably still valid.Re: MSB - Mesoblast
MSB has no income and is really a high priced biotech spekkie and I treat it as such. The trick will be to be in it for the longer term at the right time when the products are confirmed as ready to be commercialised.
For the September quarter Mesoblast reported a net loss of $US22.6 million, with cash on hand of $US116 million. It has accumulated losses of $US647.6 million since inception.
I paid part of it!!!Aussie Aussie Aussie oi oi oiYadda yadda, Novartis terminates, yadda still got our phase III yadda stems sell yadda. Down 17% .
And
That's a bill in local money
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?